9JDO

LCN2 in complex with phosphoserine

Summary for 9JDO

• Entry DOI: 10.2210/pdb9jdo/pdb
• Descriptor: Neutrophil gelatinase-associated lipocalin, PHOSPHOSERINE (2 entities in total)
• Functional Keywords: lipid binding protein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 20757.57

Authors

Qin, J.,Hu, X.,Wang, L.,Wei, H. (deposition date: 2024-08-31, release date: 2025-09-03, Last modification date: 2026-09-23)

Primary citation

Qin, J.,Hu, X.,Wang, L.,Cai, Y.,Hu, Z.,Xu, X.,Nian, Z.,Liu, Z.,Ding, X.,Jiang, Y.,Lin, Y.,Ruan, K.,Fu, B.,Tian, Z.,Zhou, Y.,Wei, H.
Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.
Cell Rep Med, :103012-103012, 2026

PubMed Abstract: Lipid metabolic reprogramming can facilitate immune escape by promoting a suppressive phenotype in tumor-infiltrating immune cells, although this process remains poorly understood. Here, we identify the lipoprotein, Lipocalin-2 (LCN2), as an essential factor driving natural killer (NK) cell dysfunction and immunosuppressive phenotype. Spatial metabolomics with crystal structure analysis demonstrates that LCN2 binding to phosphatidylserine (PS) and PS enrichment is required for tumor-associated lipid reprogramming. Increased LCN2-PS binding limits IL-15-mediated JAK-STAT pathway activation in NK cells, while inhibiting tumor-infiltrating neutrophil maintenance of anti-tumor potential in NK cells via suppression of IFN-I response. Structure-based drug screening identifies semapimod as an LCN2 inhibitor that blocks interaction with PS, disrupting the LCN2-PS immunosuppressive axis and inducing tumor control. Overall, this study uncovers a lipid metabolic reprogramming mechanism that mediates innate immune evasion and proposes a tumor treatment strategy through enhanced innate immune surveillance.

PubMed: 42664956
DOI: 10.1016/j.xcrm.2026.103012

Experimental method

X-RAY DIFFRACTION (2.85 Å)